A central feature of transmissible spongiform encephalopathies (TSE or prion diseases) involves the conversion of a normal, protease‐sensitive glycoprotein termed prion protein (PrP‐sen) into a pro‐tease‐resistant form, termed PrP‐res. The N terminus of PrP‐sen has five copies of a repeating eight amino acid sequence (octapeptide repeat). The presence of one to nine extra copies of this motif is associated with a heritable form of Creutzfeld‐Jakob disease (CJD) in humans. An increasing number of octapeptide repeats correlates with earlier CJD onset, suggesting that the rate at which PrP‐sen misfolds into PrP‐res may be influenced by these mutations. In order to determine if octapeptide repeat insertions influence the rate at which PrP‐res is formed, we used a hamster PrP amyloid‐forming peptide (residues 23–144) into which two to 10 extra octapeptide repeats were inserted. The spontaneous formation of protease‐resistant PrP amyloid from these peptides was more rapid in response to an increased number of octapeptide repeats. Furthermore, experiments using full‐length glycosylated hamster PrP‐sen demonstrated that PrP‐res formation also occurred more rapidly from PrP‐sen molecules expressing 10 extra copies of the octapeptide repeat. The rate increase for PrP‐res formation did not appear to be due to any influence of the octapeptide repeat region on PrP structure, but rather to more rapid binding between PrP molecules. Our data from both models support the hypothesis that extra octapeptide repeats in PrP increase the rate at which protease resistant PrP is formed which in turn may affect the rate of disease onset in familial forms of CJD.
The ability to predict progression to severe AKI remains an unmet challenge. Early prognostic biomarkers of AKI hold promise to improve patient outcomes by early implementation of clinical therapy, as well as unravel the pathophysiological mechanisms of AKI. Here, we present a novel urinary biomarker, IGFBP-1, that predicts the progression to severe AKI following cardiac surgery. In addition, we show that IGFBP-1 mice are protected against CIAKI, suggesting a mechanistic role for IGFBP-1 in AKI.
The complement system plays a central role in glomerular disease development and resolution. Currently, renal biopsies assess the presence of complement through limited immunofluorescence stains (C3 and C1q). With >50 total proteins and fragments involved in the complement cascade, this method offers a severely limited view into the mechanisms of tissue injury orchestrated by complement activation. A more comprehensive evaluation of complement components will advance the understanding of complement involvement in glomerular diseases by allowing for multiplex detection of complement cascade proteins and activation products, which can be achieved by mass spectrometry (MS). Data-independent acquisition MS was performed following extraction of proteins from tissue lysates, microdissected glomeruli, or protein G immunoprecipitates from residual kidney biopsy tissue. Cohorts included patients with lupus nephritis, membranous nephropathy and membranous lupus nephritis, diabetic glomerulosclerosis, C3 glomerulonephritis, and control biopsies. Abundances of complement components by MS correlated with immunofluorescence intensity of C1q on kidney biopsies. Increased abundances of complement classical, lectin, final common pathway, and regulatory proteins correlated with disease activity in lupus nephritis. Complement protein abundances of final common pathway components were heterogeneous between patients with the same disease state, including diabetic glomerulosclerosis and various forms of proliferative glomerulonephritis. Finally, complement proteins and their activation products can be mapped to determine which components are impacted among individuals and between disease states. In conclusion, complement proteins and some of their split products can be reliably measured by MS of kidney biopsies, which can enhance our understanding of complement-mediated tissue injury and heterogeneity in glomerular diseases.